Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot

Moderna (MRNA) shares surged 9% to $168 after its Phase 3 melanoma vaccine study was selected for the Presidential Symposium slot at the European Society for Medical Oncology congress on October 24. Meanwhile, Merck (MRK) gained 1% and BioNTech (BNTX) increased 2%. The selection highlights the significance of the study, although no new efficacy data was released. This offers a signal to investors that the research may lead to practice-changing developments in cancer treatment, impacting Moderna's evaluation and future opportunities.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.